Skip to main content
. 2022 Oct 23;14(21):5195. doi: 10.3390/cancers14215195

Figure 2.

Figure 2

Tumor cell proliferation (Ki67) and expression of prostate-specific antigen (PSA) as well as stromal cell expression of the androgen receptor (AR) in prostate tumor biopsies, in relation to patient survival after treatment with androgen-deprivation therapy (ADT). Tumors (n = 98) were dichotomized by immunoreactivity scores for (a) PSA at the median cut-off level (h-score of 8), (b) Ki67 (proliferation) at the median cut-off level (13%), (c) A combinatory score using the same cut-off levels as in a and b stratifying tumors into 4 groups; “Ki67 low, PSA high”, “Ki67 high, PSA high”, “Ki67 low, PSA low”, and “Ki67 high, PSA low”, of which the two middle groups were analyzed together as “Others”, and (d) AR in stromal cells at quartile levels (Q1 ≤ 10%, Q2–Q3: 10–27%, Q4 > 27%). The dichotomized tumor groups were analyzed in relation to cancer-specific survival after ADT, according to Kaplan-Meier survival analysis.